GlassScriptPhysician profile
Drew Dykes
NPI 1033779087
$10,858.59
in general payments reported to CMS, 2019-2025
16 companies · $2,639 in 2025
The $2,639 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $526 · 2022: $1,742 · 2023: $3,306 · 2024: $2,646 · 2025: $2,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,430 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,429.99 |
| Education | $160.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,274.89 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,331.73 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,194.88 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $1,113.95 | 2021-2025 | Ingrezza |
| Indivior INC. | $926.30 | 2022-2025 | Perseris, Sublocade |
| Abbvie INC. | $770.40 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $702.79 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $673.44 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $544.01 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $485.21 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $370.62 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $247.61 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $107.00 | 2021-2022 | |
| Braeburn INC. | $67.52 | 2024 | Brixadi |
| Luye Pharma (USA) LTD. | $28.16 | 2025 | Erzofri Extended-Release |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $20.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Dykes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.